Answers are grounded in this paper and cite their sources.
Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum. D. R. Bell, R. L. Woods, J. A. Levi, R. M. Fox and M. H. N. Tattersall, Aust. N.Z. J. Med., 1982,12, pp. 245–249. Thirty-seven patients with advanced ovarian cancer were treated in a prospective, randomised trial comparing chlorambucil with a combination of cyclophosphamide and cis-diamminedichloroplatinum (cis DDP). Treatment with the combination was associated with an increased overall response rate (69% versus 23%) (p = 004). A response was associated with a longer median survival but no survival advantage was demonstrated for patients who received cyclophosphamide/cis DDP. A larger study is needed to evaluate fully the potential of regimens containing cis DDP in the management of advanced ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Bell et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: